Inspire Medical Systems, Inc. (NYSE:INSP) Shares Acquired by Marshall Wace LLP

Marshall Wace LLP raised its holdings in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 1,775.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 277,131 shares of the company's stock after buying an additional 262,353 shares during the quarter. Marshall Wace LLP owned about 0.92% of Inspire Medical Systems worth $51,375,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of INSP. Geode Capital Management LLC increased its position in Inspire Medical Systems by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 483,654 shares of the company's stock valued at $102,102,000 after buying an additional 3,128 shares in the last quarter. Tidal Investments LLC purchased a new position in Inspire Medical Systems in the third quarter worth about $320,000. Synovus Financial Corp grew its holdings in shares of Inspire Medical Systems by 7.5% during the third quarter. Synovus Financial Corp now owns 3,502 shares of the company's stock valued at $739,000 after buying an additional 244 shares during the last quarter. Oddo BHF Asset Management Sas purchased a new position in Inspire Medical Systems in the 3rd quarter worth approximately $1,208,000. Finally, Principal Financial Group Inc. lifted its position in Inspire Medical Systems by 3,812.6% in the 3rd quarter. Principal Financial Group Inc. now owns 141,089 shares of the company's stock valued at $29,777,000 after acquiring an additional 137,483 shares in the last quarter. 94.91% of the stock is owned by institutional investors.

Insider Activity

In related news, CTO John Rondoni sold 583 shares of the company's stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total transaction of $99,395.67. Following the completion of the sale, the chief technology officer now directly owns 10,424 shares in the company, valued at $1,777,187.76. This represents a 5.30 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Randy Ban sold 25,584 shares of Inspire Medical Systems stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $183.50, for a total value of $4,694,664.00. Following the completion of the transaction, the insider now owns 7,259 shares in the company, valued at $1,332,026.50. This trade represents a 77.90 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.10% of the company's stock.

Inspire Medical Systems Stock Performance

NYSE:INSP traded up $1.29 during trading hours on Wednesday, reaching $150.00. The stock had a trading volume of 95,856 shares, compared to its average volume of 581,114. The stock has a market capitalization of $4.46 billion, a PE ratio of 86.71, a PEG ratio of 2.86 and a beta of 1.39. The company has a 50 day moving average price of $164.54 and a two-hundred day moving average price of $182.32. Inspire Medical Systems, Inc. has a 52 week low of $123.00 and a 52 week high of $257.40.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last posted its earnings results on Monday, February 10th. The company reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. Equities research analysts predict that Inspire Medical Systems, Inc. will post 2.16 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. KeyCorp dropped their price target on shares of Inspire Medical Systems from $234.00 to $216.00 and set an "overweight" rating on the stock in a report on Monday. Truist Financial reduced their price target on shares of Inspire Medical Systems from $250.00 to $235.00 and set a "buy" rating for the company in a research report on Tuesday, February 11th. Wells Fargo & Company decreased their price target on shares of Inspire Medical Systems from $198.00 to $195.00 and set an "equal weight" rating on the stock in a research report on Tuesday, February 11th. Stifel Nicolaus decreased their target price on Inspire Medical Systems from $190.00 to $175.00 and set a "hold" rating on the stock in a report on Monday. Finally, Royal Bank of Canada reduced their price target on Inspire Medical Systems from $260.00 to $215.00 and set an "outperform" rating for the company in a research report on Tuesday, April 15th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, Inspire Medical Systems presently has an average rating of "Moderate Buy" and an average target price of $218.90.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.